News|Articles|November 20, 2026

mRNA-1283 Associated With Lower Risk of Medically Attended COVID-19 Than BNT162b2 in Older Veterans

Listen
0:00 / 0:00

Key Takeaways

  • A VHA target-trial emulation matched by county and vaccination week (with IPTW) compared LP.8.1-formulated mRNA-1283 vs BNT162b2 in 294,499 veterans aged ≥65 years.
  • Medically attended COVID-19 occurred in 0.16% vs 0.28%, yielding adjusted rVE 35.9% (95% CrI, 20.4%–49.7%) and 10 fewer events per 10,000.
SHOW MORE

In older veterans, mRNA-1283 was associated with lower risks of medically attended COVID-19 and hospitalization than BNT162b2.

Among older US veterans vaccinated during the 2025-2026 respiratory virus season, the next-generation COVID-19 vaccine mRNA-1283 (mNEXSPIKE; Moderna) was associated with a 35.9% lower risk of medically attended COVID-19 compared with BNT162b2 (Comirnaty; Pfizer/BioNTech), according to a real-world comparative effectiveness study published in JAMA Network Open.

The vaccine was also associated with a 47.0% lower risk of COVID-19–associated hospitalization, according to Moderna.1,2

Study Compared 2 LP.8.1-Formulated mRNA Vaccines

Investigators conducted a retrospective, active-comparator-matched cohort study emulating a target trial among veterans aged 65 years and older enrolled in the Veterans Health Administration (VHA). Eligible individuals received an LP.8.1-formulated mRNA-1283 or BNT162b2 vaccine between August 27, 2025, and January 31, 2026, and were followed for up to 150 days or through May 1, 2026. Participants were matched by home county and calendar week of vaccination, and the investigators used inverse probability of treatment weighting to further reduce confounding.1,2

Of 382,185 eligible veterans, 294,499 were included in the matched analysis: 55,349 who received mRNA-1283 and 239,150 who received BNT162b2. The population had a mean age of 76.8 years, and 94.2% were male. Most participants had extensive prior vaccination, with more than 84% in each group having received a KP.2-formulated vaccine the prior season.2

Lower Risk Observed Across Outcomes

The primary outcome, medically attended COVID-19, included hospitalization, emergency department or urgent care visits, outpatient visits, and antiviral treatment. Events occurred in 86 (0.16%) mRNA-1283 recipients and 672 (0.28%) BNT162b2 recipients, corresponding to an adjusted relative vaccine effectiveness (rVE) of 35.9% (95% CrI, 20.4%-49.7%) and an absolute risk difference of 10.0 fewer events per 10,000 individuals.2

For COVID-19–associated hospitalization, 11 events occurred in the mRNA-1283 group vs 114 in the BNT162b2 group (rVE, 47.0%; 95% CrI, 5.4%-74.8%). Point estimates also favored mRNA-1283 for emergency or urgent care visits (rVE, 35.1%), outpatient visits (39.0%), and antiviral treatment (40.1%).

Most of the difference between groups accrued after 90 days, and sensitivity analyses produced similar estimates, ranging from about 33% to 37%. In an exploratory analysis, mRNA-1283 was associated with a 39.3% lower risk of hospitalization for major adverse cardiovascular events, including myocardial infarction, stroke, or heart failure, which the authors said should be interpreted cautiously.1,2

Findings Build on Earlier Clinical and Real-World Data

The FDA approved mRNA-1283 in May 2025 for previously vaccinated adults aged 65 years and older and individuals aged 12 to 64 years with at least 1 underlying risk factor for severe COVID-19.

The approval was based on the phase 3 NextCOVE trial (NCT05815498), which enrolled approximately 11,400 participants and found that a 10-μg dose of mRNA-1283 had a 9.3% higher relative vaccine efficacy than a 50-μg dose of mRNA-1273 (Spikevax; Moderna), with a 13.5% higher relative efficacy among adults aged 65 years and older in a descriptive subgroup analysis.3

Earlier real-world data in adults aged 65 years and older showed absolute vaccine effectiveness against COVID-19–related hospitalization of 59.3% for mRNA-1283 and 48.3% for BNT162b2, although those authors noted that each vaccine was compared with its own unvaccinated group and the study was not designed as a head-to-head comparison. The current analysis offers a direct comparison between the 2 products.2,4

Limitations and Industry Support

Because the study was observational, the findings are associative, and residual confounding may remain from factors such as testing behavior, undocumented prior infection, and vaccine availability. Some negative-control outcomes also showed associations, although smaller than those for COVID-19. The predominantly older, male VHA population may limit generalizability.

The authors also emphasized that the results reflect added protection from one product over another, not the overall benefit of vaccination. Moderna supported the study and contributed to its design, interpretation, and manuscript preparation, although the company stated it did not conduct the study or collect, manage, or analyze the data.1-3

Implications for Pharmacists

Older adults continue to carry a substantial COVID-19 burden. The CDC estimates there were between 120,000 and 250,000 COVID-19 hospitalizations from October 2025 through early May 2026, yet only 31% of adults aged 65 to 74 years and 37% of those aged 75 years and older received a COVID-19 vaccine during the 2025-2026 season. The study authors suggested the findings may inform seasonal vaccine selection for high-risk older adults.2,5

When counseling patients, pharmacists should note that mRNA-1283 had a safety profile similar to mRNA-1273 in clinical trials, with fewer local reactions; the most common adverse effects were injection site pain, fatigue, headache, and myalgia.3

Expert Insights

In an interview with Pharmacy Times, Francesca Ceddia, MD, chief medical affairs officer at Moderna, talked about what the findings mean for pharmacists who vaccinate older adults against COVID-19.

Pharmacy Times: Most of the difference between mRNA-1283 and BNT162b2 accrued after 90 days. What might explain that pattern, and what does it suggest about the durability of protection and vaccine timing for older adults?

Francesca Ceddia, MD: One of the particularly interesting findings from this study is that the difference in protection between the two vaccines became more apparent over time, particularly after 90 days. This raises the possibility that mNEXSPIKE may offer an advantage in maintaining protection over time, which is especially relevant for older adults at greater risk of severe COVID-19 outcomes. While the study was not designed to evaluate differences in waning protection or the biological mechanisms underlying this finding, the results are encouraging and warrant further investigation.

From a public health perspective, these findings highlight the importance of maintaining protection throughout the respiratory virus season. Importantly, they should not be interpreted as a reason to delay vaccination but rather as additional evidence that may inform vaccine selection for older adults.

Pharmacy Times: Given the observational design, the predominantly male veteran population, and Moderna's involvement, how should pharmacists weigh these findings when choosing a COVID-19 vaccine for patients aged 65 years and older?

Ceddia: Real-world evidence complements randomized clinical trials by helping us understand how vaccines perform in clinical practice. This study adds meaningful evidence from nearly 295,000 older adults in a population with a substantial burden of underlying medical conditions, placing many participants at increased risk of severe COVID-19 outcomes. In the population studied, mNEXSPIKE was associated with an estimated 35.9% greater relative effectiveness against medically attended COVID-19 and 47.0% against COVID-19-associated hospitalization compared with BNT162b2 over 150 days.

As an observational real-world analysis, the study is subject to residual confounding, including differences in testing behavior, undocumented prior infection, and vaccine availability. The predominantly older, male VHA population may limit generalizability to broader populations. Findings are associative and do not establish causality. While the study was supported by Moderna, independent academic investigators were responsible for conducting the research and analyzing the data.

For pharmacists, these results provide additional evidence in a clinically vulnerable population to be considered alongside the totality of available evidence, individual patient considerations, and current recommendations. Ultimately, the priority remains ensuring timely vaccination with an appropriate, recommended vaccine.

Pharmacy Times: Only about one-third of older adults received a COVID-19 vaccine last season. What can pharmacists do at the counter to close that gap heading into the 2026-2027 season?

Ceddia: The vaccination gap among older adults remains a significant public health concern, particularly given their increased vulnerability to severe COVID-19 outcomes and hospitalization.

Pharmacists are uniquely positioned to help close this gap. As among the most accessible and trusted healthcare professionals, they have frequent opportunities to engage older adults, particularly those managing chronic conditions. Proactive, personalized recommendations, routine assessment of vaccination status, and open conversations addressing questions about vaccine effectiveness and safety can help build confidence and support informed vaccination decisions.

Importantly, we should move the conversation beyond preventing infection to protecting what matters most to older adults: their health, independence, and quality of life. By making vaccination discussions a routine part of patient interactions and reducing barriers to access, pharmacists can help translate everyday encounters into opportunities for timely vaccination.

Ultimately, closing the vaccination gap requires both continued innovation in vaccine protection and ensuring that eligible individuals have the information and access they need to benefit from it.

REFERENCES
1. Moderna announces JAMA Network Open publication of real-world comparative effectiveness data for mNEXSPIKE (COVID-19 vaccine, mRNA) in adults aged 65 years and older. News release. Moderna, Inc. November 11, 2026. Accessed November 18, 2026. https://www.biospace.com/press-releases/moderna-announces-jama-network-open-publication-of-real-world-comparative-effectiveness-data-for-mnexspike-covid-19-vaccine-mrna-in-adults-aged-65-years-and-older
2. McConeghy KW, Skov B, DeVone F, et al. Estimation of mRNA-1283 vs BNT162b2 COVID-19 vaccine effectiveness in older US veterans. JAMA Netw Open. 2026;9(11):e2644727. doi:10.1001/jamanetworkopen.2026.44727
3. Moderna receives US FDA approval for COVID-19 vaccine mNEXSPIKE. News release. Moderna, Inc. May 31, 2025. Accessed November 18, 2026. https://www.newswire.com/news/moderna-receives-u-s-fda-approval-for-covid-19-vaccine-mnexspike
4. Vicic N, Bogdanov A, Hensler H, et al. Interim effectiveness of 2025–2026 mRNA-1283 and BNT162b2 COVID-19 vaccines against COVID-19–related outcomes among adults aged ≥65 years in the United States. Infect Dis Ther. 2026;15(9):2307-2318. doi:10.1007/s40121-026-01395-4
5. COVID-19 for healthcare providers. American Lung Association. Accessed November 18, 2026. https://www.lung.org/hcp-covid

Related to this article